Author

Y. Jansen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:differential expression· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

C. Weber· 2 shared L. Maegdefessel· 2 shared A. Faussner· 1 shared A. Hoffmann· 1 shared A. Kaltenbach· 1 shared A. Kapurniotu· 1 shared A. Prabhu· 1 shared B. Chen· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

C. Weber

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Endothelial cannabinoid CB1 receptor deficiency reduces arterial inflammation and lipid uptake in response to atheroprone shear stress

B. Chen, A. Prabhu, G. Li, A. Kaltenbach, Y. Wang, G. Shakir, L. Natarelli, R. Megens, Y. Jansen, S. Ramanathan, M. Geiger, A. Faussner, M. Hristov, D. Richter, X. Di, , S. Steffens

This paper shows that blocking endothelial CB1 receptors reduces arterial inflammation and lipid uptake under atheroprone shear stress, suggesting potential therapeutic benefits for atherosclerosis.

bioRxiv · May 15, 2024 · PreprintImmunology

MIF-2/D-DT is an atypical atherogenic chemokine that promotes advanced atherosclerosis and hepatic lipogenesis

O. El Bounkari, C. Zan, J. Wagner, E. Bugar, P. Bourilhon, C. Kontos, M. Zarwel, D. Sinitski, J. Milic, Y. Jansen, W. Kempf, L. Maegdefessel, A. Hoffmann, M. Brandhofer, R. Bucala, , J. Bernhagen

This study identifies MIF-2 as an atherogenic chemokine that promotes atherosclerosis and hepatic lipogenesis by acting through CXCR4 and SREBP pathways.

bioRxiv · Dec 28, 2021 · PreprintImmunology